Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research

主旨 癌症研究 间质细胞 化学 酪氨酸激酶 药理学 医学 酪氨酸激酶抑制剂 不利影响 胃肠道 临床研究阶段 琥珀酸脱氢酶 信号转导 脂质代谢 临床试验 激酶 伊马替尼 脂滴 受体酪氨酸激酶 内科学 靶向治疗 癌症 酪氨酸 脂肪酸 动物研究 乳酸脱氢酶 体内 生物 机制(生物学) CD36 磷酸化
作者
Hai-Bo Qiu,Zhiyan Liang,Jing Yang,Ye Zhou,Zhiwei Zhou,Xiangbin Wan,Ning Li,Kaixiong Tao,Yong Li,Xin Wu,Yang Chen,Zi Chen,Hengbang Wang,Lichuang Men,Yan Xiong,Lihui Liu,Dajun Yang,Yifan Zhai,Rui‐Hua Xu
出处
期刊:Signal Transduction and Targeted Therapy [Springer Nature]
卷期号:10 (1): 361-361 被引量:6
标识
DOI:10.1038/s41392-025-02456-9
摘要

Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) are generally resistant to targeted therapy with tyrosine kinase inhibitors (TKIs), such as imatinib, and there are no standard therapeutic options for advanced SDH-deficient GISTs. The precise oncogenic mechanisms of SDH mutations in GIST have not been elucidated. Olverembatinib, a novel multikinase inhibitor, has shown promising activity in treating imatinib-resistant GIST. We conducted a phase 1 study (NCT03594422) to evaluate the safety and antitumor activity of olverembatinib in 66 patients with unresectable/metastatic GIST/other solid tumors, including 26 with TKI-failed SDH-deficient GISTs. To our knowledge, this is the largest prospective clinical trial for this rare GIST subtype. The median follow-up was 14.5 (0.9-57.5) months. Olverembatinib was well tolerated; treatment-emergent adverse events (≥20%) included increases in hepatic transaminases, increases in leukocytes and neutrophils, anemia, and pyrexia. For SDH-deficient GISTs, confirmed partial responses were observed in 6 of the 26 evaluable patients (objective response rate, 23.1%; 95% CI, 9-43.7); an additional 16 (61.5%) did not progress during the first 6 months of treatment. This resulted in a clinical benefit rate of 84.6% (95% CI, 65.1-95.6), and the median progression-free survival was 25.7 months (95% CI, 12.9-NR). As a putative mechanism of action, translational research revealed significant lipid enrichment with the overexpression of lipid uptake-related genes and proteins, including CD36, fatty acid binding proteins, fatty acid transport proteins, and lipid metabolites, in SDH-deficient GIST patients, and olverembatinib suppressed lipid uptake and CD36 expression in GIST cells. Olverembatinib also exerts antitumor effects by inhibiting tumorigenic signaling pathways associated with hypoxia, angiogenesis, proliferation, and survival.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aaaaa发布了新的文献求助10
刚刚
我是老大的应助被Rony采纳,获得10
刚刚
dildil发布了新的文献求助10
1秒前
1秒前
Ava的应助被Chelseacyh采纳,获得10
2秒前
2秒前
2秒前
3秒前
3秒前
dd完成签到,获得积分10
4秒前
Dc完成签到,获得积分10
4秒前
李健的应助被小马采纳,获得10
4秒前
JackieLiu的应助被默默惜霜采纳,获得10
4秒前
科研通AI6.2的应助被默默惜霜采纳,获得10
4秒前
ephemeral发布了新的文献求助10
4秒前
元吉的应助被默默惜霜采纳,获得10
4秒前
秋风的应助被默默惜霜采纳,获得10
5秒前
5秒前
小蘑菇的应助被勤恳的小甜瓜采纳,获得10
5秒前
5秒前
5秒前
自己完成签到,获得积分10
6秒前
科研小趴菜完成签到,获得积分10
6秒前
耍酷季节的应助被IY采纳,获得30
6秒前
7秒前
领导范儿的应助被钦钦小豆包采纳,获得10
8秒前
H11103y发布了新的文献求助10
8秒前
钟梓袄发布了新的文献求助10
8秒前
9秒前
hhh完成签到,获得积分10
10秒前
天天快乐的应助被Present采纳,获得10
10秒前
李健的应助被田浩阳采纳,获得10
10秒前
10秒前
10秒前
顺利毕业发布了新的文献求助10
11秒前
11秒前
11秒前
Lucas的应助被背后的半山采纳,获得10
11秒前
123完成签到 ,获得积分10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572434
关于积分的说明 21825655
捐赠科研通 7779988
什么是DOI,文献DOI怎么找? 3433852
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480148